Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses
Latika Singh, Natalia Zabavnik, Sambasivan Venkatasubramanian, Sagi Barzilai, Jing Ni, Andreas Evers, Olga Bogatyrova, Melissa G. Derner, Stefan Zielonka, Rinat Zaynagetdinov, Laura Helming · 2026
Read Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses by Latika Singh, Natalia Zabavnik, Sambasivan Venkatasubramanian, Sagi Barzilai, Jing Ni, Andreas Evers, Olga Bogatyrova, Melissa G. Derner, Stefan Zielonka, Rinat Zaynagetdinov, Laura Helming (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13476703.txt.
Description
Latika Singh and co-authors build a two-in-one antibody in 2026 that blocks a checkpoint and traps a calming cytokine at once. The cytokine, IL-10, can aid or hinder tumor immunity depending on its level. At patient-like levels it damped T cell work in lab tests. The new antibody fuses a PD-L1 blocker to a trap for IL-10.
Treated T cells resisted IL-10 damping and fired up more strongly than with either part alone. Helper immune cells also shifted toward a mature, active state. Killer T cell activation beat checkpoint care alone and beat the loose mix of parts. Dual targeting may rescue patients whom single checkpoints fail.
Catalog record
| CREATOR | Latika Singh, Natalia Zabavnik, Sambasivan Venkatasubramanian, Sagi Barzilai, Jing Ni, Andreas Evers, Olga Bogatyrova, Melissa G. Derner, Stefan Zielonka, Rinat Zaynagetdinov, Laura Helming |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |